Pacer Advisors’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $23M | Buy |
41,003
+27,038
| +194% | +$17.3M | 0.06% | 286 |
|
|
2025
Q4 | $9.45M | Buy |
13,965
+1,269
| +10% | +$864K | 0.02% | 508 |
|
|
2025
Q3 | $8.11M | Sell |
12,696
-473
| -4% | -$287K | 0.02% | 536 |
|
|
2025
Q2 | $7.06M | Buy |
13,169
+4,825
| +58% | +$2.31M | 0.02% | 588 |
|
|
2025
Q1 | $3.5M | Sell |
8,344
-2,427
| -23% | -$1.05M | 0.01% | 773 |
|
|
2024
Q4 | $4.45M | Sell |
10,771
-2,971
| -22% | -$1.3M | 0.01% | 656 |
|
|
2024
Q3 | $6.94M | Buy |
13,742
+1,729
| +14% | +$840K | 0.01% | 552 |
|
|
2024
Q2 | $5.85M | Buy |
12,013
+2,416
| +25% | +$1.21M | 0.01% | 549 |
|
|
2024
Q1 | $5.18M | Sell |
9,597
-2,030
| -17% | -$1.11M | 0.01% | 569 |
|
|
2023
Q4 | $6.45M | Sell |
11,627
-10,359
| -47% | -$4.86M | 0.02% | 508 |
|
|
2023
Q3 | $9.61M | Buy |
21,986
+850
| +4% | +$424K | 0.04% | 333 |
|
|
2023
Q2 | $10.6M | Sell |
21,136
-5,605
| -21% | -$2.69M | 0.04% | 362 |
|
|
2023
Q1 | $13.4M | Buy |
26,741
+24,069
| +901% | +$11.5M | 0.06% | 320 |
|
|
2022
Q4 | $1.09M | Sell |
2,672
-1,633
| -38% | -$634K | 0.01% | 787 |
|
|
2022
Q3 | $1.4M | Buy |
4,305
+112
| +3% | +$41.1K | 0.01% | 467 |
|
|
2022
Q2 | $1.47M | Sell |
4,193
-8,782
| -68% | -$3.58M | 0.01% | 474 |
|
|
2022
Q1 | $7.1M | Buy |
12,975
+4,782
| +58% | +$2.52M | 0.06% | 338 |
|
|
2021
Q4 | $5.39M | Sell |
8,193
-687
| -8% | -$431K | 0.06% | 329 |
|
|
2021
Q3 | $5.52M | Buy |
8,880
+294
| +3% | +$198K | 0.07% | 339 |
|
|
2021
Q2 | $5.42M | Buy |
8,586
+1,086
| +14% | +$600K | 0.08% | 325 |
|
|
2021
Q1 | $3.67M | Sell |
7,500
-837
| -10% | -$419K | 0.06% | 323 |
|
|
2020
Q4 | $4.17M | Sell |
8,337
-5,157
| -38% | -$2.31M | 0.08% | 223 |
|
|
2020
Q3 | $5.3M | Sell |
13,494
-2,164
| -14% | -$800K | 0.11% | 141 |
|
|
2020
Q2 | $5.17M | Buy |
15,658
+8,697
| +125% | +$2.52M | 0.1% | 145 |
|
|
2020
Q1 | $1.85M | Buy |
6,961
+204
| +3% | +$53.2K | 0.04% | 164 |
|
|
2019
Q4 | $1.76M | Sell |
6,757
-8,967
| -57% | -$2.36M | 0.08% | 318 |
|
|
2019
Q3 | $4.28M | Buy |
15,724
+1,315
| +9% | +$366K | 0.1% | 209 |
|
|
2019
Q2 | $3.97M | Buy |
14,409
+1,935
| +16% | +$477K | 0.1% | 207 |
|
|
2019
Q1 | $2.79M | Buy |
+12,474
| New | +$2.58M | 0.08% | 235 |
|
|
2018
Q4 | – | Sell |
-8,068
| Closed | -$2.01M | – | 781 |
|
|
2018
Q3 | $2.01M | Buy |
8,068
+1,348
| +20% | +$327K | 0.08% | 325 |
|
|
2018
Q2 | $1.46M | Buy |
6,720
+1,142
| +20% | +$235K | 0.07% | 424 |
|
|
2018
Q1 | $1.07M | Buy |
5,578
+962
| +21% | +$178K | 0.06% | 436 |
|
|
2017
Q4 | $722K | Buy |
4,616
+1,179
| +34% | +$186K | 0.05% | 560 |
|
|
2017
Q3 | $534K | Buy |
3,437
+411
| +14% | +$65K | 0.05% | 647 |
|
|
2017
Q2 | $488K | Buy |
3,026
+343
| +13% | +$55.7K | 0.05% | 617 |
|
|
2017
Q1 | $415K | Buy |
2,683
+1,010
| +60% | +$139K | 0.05% | 600 |
|
|
2016
Q4 | $196K | Sell |
1,673
-10
| -0.6% | -$1.14K | 0.03% | 869 |
|
|
2016
Q3 | $190K | Sell |
1,683
-6,759
| -80% | -$712K | 0.03% | 843 |
|
|
2016
Q2 | $784K | Buy |
8,442
+7,067
| +514% | +$607K | 0.12% | 160 |
|
|
2016
Q1 | $108K | Buy |
1,375
+39
| +3% | +$2.81K | 0.02% | 587 |
|
|
2015
Q4 | $97K | Buy |
+1,336
| New | +$95.3K | 0.02% | 603 |
|
Other funds holding IDXX
VCM
VPM
Pacer Advisors's IDXX Position: Q1 2026 in Review
Pacer Advisors increased its Idexx Laboratories (IDXX) stake by 194% in Q1 2026, buying an estimated $17.3M and bringing the position to 41,003 shares worth $23M. The position accounts for 0.06% of the portfolio, ranked #286.
Pacer Advisors first reported a position in IDXX in Q4 2015 and has held it in 41 quarters since. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.
- Pacer Advisors held 41,003 shares of Idexx Laboratories worth $23M as of Q1 2026.
- Pacer Advisors bought 27,038 Idexx Laboratories shares in Q1 2026, an estimated $17.3M.
- Idexx Laboratories made up 0.06% of Pacer Advisors's portfolio in Q1 2026, its #286 holding.
- Pacer Advisors first reported a position in Idexx Laboratories in Q4 2015 and has held it in 41 quarters since.
- 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.
Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.